These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37119376)

  • 1. Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy.
    Chow KW; Ibrahim BM; Yum JJ; Dang A; Dang L; Chen KT; Jackson NJ; Saab S
    Dig Dis Sci; 2023 Jun; 68(6):2389-2397. PubMed ID: 37119376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.
    Pantham G; Post A; Venkat D; Einstadter D; Mullen KD
    Dig Dis Sci; 2017 Aug; 62(8):2166-2173. PubMed ID: 28560484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.
    Frenette CT; Levy C; Saab S
    Dig Dis Sci; 2022 Jun; 67(6):1994-2004. PubMed ID: 34169435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
    Rahimi RS; Singal AG; Cuthbert JA; Rockey DC
    JAMA Intern Med; 2014 Nov; 174(11):1727-33. PubMed ID: 25243839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.
    Bajaj JS; Sanyal AJ; Bell D; Gilles H; Heuman DM
    Aliment Pharmacol Ther; 2010 May; 31(9):1012-7. PubMed ID: 20136802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose.
    Sharma P; Sharma BC
    Saudi J Gastroenterol; 2011; 17(2):138-41. PubMed ID: 21372353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Agrawal A; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2011 Jun; 26(6):996-1003. PubMed ID: 21129028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
    Volk ML; Burne R; Guérin A; Shi S; Joseph GJ; Heimanson Z; Ahmad M
    J Med Econ; 2021; 24(1):202-211. PubMed ID: 33464935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.
    Aires FT; Ramos PT; Bernardo WM
    Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Gluud LL; Vilstrup H; Morgan MY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003044. PubMed ID: 27153247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactulose a day keeps encephalopathy at bay.
    Klinken E; MacQuillan G
    J Gastroenterol Hepatol; 2011 Jun; 26(6):939-40. PubMed ID: 21564285
    [No Abstract]   [Full Text] [Related]  

  • 19. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
    Shen YC; Chang YH; Fang CJ; Lin YS
    Nutr J; 2019 Jul; 18(1):34. PubMed ID: 31279342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.